Buy Rilmazafone (CAS 99593-25-6) is an open-ring peptide aminobenzophenone that functions as a highly water-soluble prodrug to the triazolobenzodiazepine class . Unlike traditional lipophilic benzodiazepines, rilmazafone lacks a closed diazepine ring in its parent structure, rendering it inactive at γ-aminobutyric acid type A (GABA_A) receptors prior to metabolic activation [1]. Upon oral or systemic administration, it undergoes enzymatic cleavage by intestinal aminopeptidases followed by spontaneous cyclization to form active metabolites, primarily rilmazolam [1]. This distinct structural profile provides significant procurement advantages for researchers requiring aqueous formulation compatibility, delayed in vivo activation, and a lack of direct in vitro receptor binding.

Substituting rilmazafone with direct-acting in-class analogs like triazolam or estazolam fundamentally alters both formulation chemistry and assay baselines [1]. Traditional triazolobenzodiazepines are highly lipophilic, necessitating the use of organic co-solvents (e.g., propylene glycol or ethanol) that can induce precipitation, alter cellular osmolarity, or cause injection-site artifacts in vivo . Furthermore, because generic substitutes possess intrinsic nanomolar affinity for GABA_A receptors, they cannot be used as negative controls in in vitro binding assays or as tools to isolate aminopeptidase-dependent metabolic activation pathways [1]. Procurement of rilmazafone is therefore strictly required when aqueous processability and prodrug-specific pharmacokinetic delays are critical to the experimental design.